Key Highlights

  • Bone Biologics stockholders approved a Reverse Stock Split at a ratio between 1-for-2 and 1-for-10, set by the board.
  • The reverse split proposal received 806,603 votes for, 137,720 against and 7,423 abstentions at the September 28 annual meeting.
  • Stockholders also approved issuing shares underlying warrants tied to a July 7, 2026 purchase agreement under Nasdaq Rule 5635(d).
  • Four directors were elected, executive pay was approved, and Weinberg & Company, P.A. was ratified as auditor.

Bone Biologics Corp (NASDAQ:BBLG)'s stockholders approved a reverse stock split at a ratio to be set by the board between 1-for-2 and 1-for-10, and approved the issuance of common stock underlying certain warrants under Nasdaq Rule 5635(d), at the company's annual meeting on September 28, 2026. The results were reported in a Form 8-K filed September 29, 2026 under Item 5.07. Stockholders also elected four directors, ratified Weinberg & Company, P.A. as auditor and approved an advisory pay vote.

The filing reports 2,011,057 shares outstanding and 951,746 shares present or represented by proxy, or 47.3%, which was enough to establish a quorum. The company notes that broker non-votes were 758,866 on the proposals where they apply.

Reverse Split

The reverse split proposal authorizes an amendment to the company's charter to effect a split at a ratio of not less than 1-for-2 and not more than 1-for-10, in the board's discretion. It received 806,603 votes for, 137,720 against and 7,423 abstentions. The approval gives the board a range; it is not itself a split. As an arithmetic illustration only, and not a figure from the filing, combining 2,011,057 shares at 1-for-2 would leave about 1.0 million shares and at 1-for-10 about 201,000.

Warrant Share Issuance

The Warrant proposal approved, for purposes of Nasdaq Rule 5635(d), the issuance of common stock underlying warrants connected to a Securities Purchase Agreement dated July 7, 2026 and to the H.C. Wainwright engagement letter dated March 11, 2025, as amended. The filing refers to the relevant threshold as 20% of the company's common stock outstanding. Rule 5635(d) generally requires Shareholder approval for certain non-public issuances at or above that level and below a specified price. The proposal received 147,340 votes for, 42,233 against and 3,307 abstentions, with 758,866 broker non-votes.

Directors, Pay and Auditor

Four nominees were elected to serve until the next annual meeting. Bruce Stroever received 152,615 votes for and 3,941 withheld. Siddhesh Angle received 155,570 for and 3,842 withheld. Robert Gagnon received 158,799 for and 3,892 withheld. Philip Meikle received 158,783 for and 3,891 withheld. Each nominee had 758,866 broker non-votes.

The advisory vote on executive compensation was approved, with 139,592 votes for, 49,851 against, 3,437 abstentions and 758,866 broker non-votes. The ratification of Weinberg & Company, P.A. as independent registered public accounting firm for the year ending December 31, 2026 received 898,011 votes for, 49,834 against and 3,901 abstentions.

A sixth proposal authorized adjournment of the meeting to solicit more proxies if needed. It also passed, with 806,477 votes for, 137,919 against and 7,350 abstentions, but the filing states that the adjournment was not necessary because all the other proposals were approved.

Jeffrey Frelick, the company's Chief Executive Officer, signed the 8-K on September 29, 2026. The company lists its address as 2 Burlington Woods Drive, Suite 100, Burlington, Massachusetts 01803.

Bone Biologics' Board Decision on the Split Ratio

Because the reverse split range is only an authorization, the next thing to look for is any board decision on the ratio and timing, which would be disclosed in a later filing or announcement. Similarly, the warrant issuance approval permits shares to be issued under the referenced agreements, and later filings may show how many are issued. The current report sets no dates for either action.